Testicular cancer trial: could a stronger chemo course cut relapse risk?

NCT ID NCT02341989

Ongoing Disease control Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether one course of BEP chemotherapy works better than one course of carboplatin to prevent seminoma testicular cancer from coming back after surgery. It includes 348 men with stage I seminoma who have risk factors like a large tumor or rete testis invasion. The study compares relapse rates and side effects between the two treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bleomycin, etoposide, and cisplatin (BEP) or carboplatin
What this could lead to: If BEP works better, it could offer a more effective single-course option to prevent seminoma from coming back after surgery.
What could go wrong: This is an early-phase comparison; BEP may cause more side effects than carboplatin, and the trial is not yet complete. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEMINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm of testis Recurrence seminoma testicular cancer testicular seminoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEMINOMA TESTICULAR NEOPLASMS

Contacts and locations

Locations

Institutt for kreftforskning og molekylær medisin, St Olavs Hospital

Trondheim, Norway
St. Olavs University hospital HF

Trondheim, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.